Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B

Po-Ke Hsu1,2, Pei-Yuan Su1 and Chia-Lin Wu3,4,5*

Abstract
Background/Aims: Entecavir (ETV) can suppress chronic hepatitis B (CHB) virus replication as a standard of treatment drugs. For the treatment of CHB, affordable generic drugs may be more widely used in developing and undeveloped countries. However, there is little real-world data regarding the clinical efficacy of switching from entecavir-brand-name drugs (ETV-Brand) to entecavir generic drugs (ETV-Generic) with 0.5 mg once daily. The aim of the study was to evaluate the antiviral activity and safety of ETV-Generic in comparison to ETV-Brand in CHB-patients.

Methods: In this single-center, retrospective, 175 treatment-naïve—CHB patients were assigned to receive 0.5 mg of ETV-Brand per day for at least 2 years and then switched to ETV-Generic for 6 months for analysis. The primary efficacy endpoint was a sustained virological response in comparison of the rate of undetectable serum Hepatitis B deoxyribonucleic acid (HBV DNA) as the sustained virologic response at baseline and 6 months after switching. Secondary efficacy endpoints were the comparison of the alanine aminotransferase (ALT) levels between before and after switching and ALT normalization. Renal safety consideration was reported on changing the estimated glomerular filtration rate.

Results: From baseline to 6 months, the rate of undetectable HBV DNA and ALT levels remained stable as compared ETV-Brand period with ETV-Generic for 6 months. The rate of undetectable HBV DNA were 81.1% in ETV-Brand versus 88.0% in ETV-Generic (p = 0.05 CI 0.1–13.5%). ALT levels were 27.2 IU/L (CI 24.8–29.6 IU/L) in ETV-Brand versus 26.2 IU/L (CI 24.0–28.4 IU/L) in ETV-Generic (p = 0.55). Both endpoints were not significantly different between ETV-Brand and ETV-Generic treatments. Kidney function did not significantly differ from ETV-Brand (80.8, interquartile range [IQR]: 66.6–95.3 mL/min/1.73 m²) to ETV-Generic treatment period (80.3, IQR: 65.6–93.5 mL/min/1.73 m²).

Conclusion: In treatment-naïve CHB-patients, the efficacy and safety profiles of switching from ETV-Brand to ETV-Generic showed no difference. Concluding the ETV-Generic comes to exciting virologic responses and rare adverse events.

Keywords: Chronic hepatitis B, Generic drugs, Entecavir

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
with the implementation of the Viral Hepatitis Control Program (VHCP) in the 1970s and the launch of the universal vaccination program in 1984, the HBV infection rate among the general population dropped significantly from 15–20 to 1% [7–11].

The standard of chronic hepatitis B (CHB) treatment is to suppress the amount of HBV virus. By inhibiting the quantity and activity of HBV, it reduces inflammation and prevents fibrosis, liver cirrhosis, liver failure and even HCC. Thereby, it is possible to reduce mortality due to liver disease and to improve the survival rate. The treatment goal is loss of hepatitis B surface antigen (HBsAg), but complete eradication of HBV is nearly impossible, because nuclear covalently closed circular DNA (cccDNA) remains in the liver cell [12, 13]. In clinical practice, normalization of alanine aminotransferase (ALT), undetectable serum HBV DNA, and improvement of histological inflammation or fibrosis are indicators of treatment response [14].

Entecavir (ETV) is a deoxyguanosine nucleoside analog which exerts antiviral effects by inhibiting three steps of replication: priming of HBV DNA polymerase, reverse transcription of the HBV DNA negative strand from pregenomic mRNA, and synthesis of the HBV DNA positive strand [15]. Generic ETV (ETV-Generic) had been introduced to the market since 2019 in Taiwan and with an advantage of a lower price that more CHB-patients can be treated.

Envir® is a generic ETV drug developed by China Chemical & Pharmaceutical (CCPC) equivalent in laboratory tests to the brand-name ETV drug (Baraclude®, ETV-Brand) by Bristol-Myers Squibb (BMS). Previous studies similar antiviral efficacy with regard to switching from brand-name to generic ETV 1 mg for antiviral-resistant chronic hepatitis B [16, 17]. Due to the influence of Taiwan's insurance policy, the utilization rate of Generic ETV (ETV-Generic) has greatly increased in recent years. However, there is a lack of real-world data evaluating the efficacy and safety of switching from brand-name to generic ETV 0.5 mg for controlling CHB. Therefore, the current study was designed to compare the antiviral efficacy and safety between lower dose brand-name and generic ETV in CHB-patients.

Materials and methods
Study design
This study was conducted using a single-center retrospective real-world medical database in Changhua Christian Hospital from January 1, 1999, to December 31, 2019. All patients were treated or followed in the hospital. In December 2018, stable CHB-patients under the treatment of 0.5 mg ETV-Brand were informed to switch the treatment to 0.5 mg ETV-Generic. All the informed consents of the participants were given before changing their treatment. Then their treatment was changed for 1 year (from January 1, 2019, to December 31, 2019). After switching for 1 year, our retrospective study compared patient efficacy and safety using hospital medical databases. The study was carried out in compliance with the declaration of Helsinki and was approved by the Institutional Review Board of Changhua Christian Hospital (approval number: 210202). The study was performed in compliance with good clinical practices, according to the International Conference on Harmonization (ICH) guidelines.

Patient enrollment
Inclusion criteria were male and female patients of ages 18–75 years who were diagnosed as HBsAg-positive since January 1, 1999, to December 31, 2019 and had a medical record of CHB under the ETV-Brand for 2 years. No other anti-viral medications during the study period of time were recorded. Exclusion criteria included: (1) Age < 18 years; (2) Transfer to other hospital; (3) Virologic resistance to ETV-Brand; (4) Switching to Tenofovir; (5) Switching time less than 48 weeks (without enough observation time). Finally, 175 patients were eligible for the analysis of effectiveness and renal safety (Fig. 1).

Study outcome
Sustained virologic response and alanine aminotransferase (ALT) stabilization
The primary endpoint was evaluated by sustained virologic response rate defined by undetectable HBV DNA which means HBV DNA viral load < 10 IU/mL between baseline (on 0.5 mg ETV-Brand for at least 6 months) and after switching to 0.5 mg ETV-Generic for 6 months. The secondary endpoint was evaluated by comparing the serum ALT levels before and after switching (ALT normalization).

Renal safety
Comparison of renal safety of ETV-Brand and ETV-Generic was defined as the renal function (eGFR) before switching and after switching for 6 months.

Statistical analysis
All efficacy analyses were performed on the full analysis set. The population included all analytical subjects who received at least once daily dose of ETV-Brand for 2 years as baseline characteristics. For sample size calculation, a one-sided α level of 0.025 and 80% power, a sample size of 102 patients was estimated with a noninferiority margin of one. Considering a 20% drop-out rate, the study will require a total of 126 patients.
For the primary efficacy of sustained virologic response rate and secondary efficacy of ALT level change, we use paired $t$-test for comparing the two treatment modalities. Change in renal function (eGFR) between the two treatment modalities was also analyzed by using paired $t$-test. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and MedCalc® Statistical Software version 20.008 (MedCalc Software Ltd, Ostend, Belgium; https://www.medcalc.org; 2021).

Results

Baseline characteristics

The median age of the included patients was 61 (IQR: 52.5–68.8) years, and male sex was predominant (68.0%). The median treatment period of CHB with ETV was 3.2 (IQR: 2.7–4.3) years, and all patients were treatment-naïve. The rate of HBeAg positivity was 19.4%. And the median Fibrosis-4 (FIB-4) Index for Liver Fibrosis was 2.7 (IQR: 2.2–3.0). Mean detectable HBV DNA level showed 14.0 (12.4–16.5) IU/mL, see Table 1.

Primary end point of efficacy: comparison of sustained virologic response rate between initial baseline data and 6 months data of the treatment of ETV-Generic

After 2 years treatment of ETV-Brand as the proportion of patients with undetectable HBV DNA and comparing

---

Table 1 Baseline characteristics of the patients included in study group

| Characteristic                  | Initial treatment of ETV-Brand |
|---------------------------------|-------------------------------|
| Age, years                      | 61 (52.5–68.8)                |
| Male sex, n (%)                 | 119/175 (68.0%)               |
| BMI, kg/m²                      | 24.3 (22.2–27)                |
| Period of ETV-Brand(years)      | 3.2 (2.7–4.3)                 |
| WBC, × 10³/μL                   | 5.8 (4.4–7.3)                 |
| HB, g/dL                        | 13.8 (12.7–14.6)              |
| Platelet, × 10³/μL              | 145 (104–191)                 |
| ALT, U/L                        | 24 (18–32)                    |
| AST, U/L                        | 29 (24–36)                    |
| Total bilirubin, mg/dL          | 0.8 (0.6–1.1)                 |
| eGFR, mL/min/1.73 m²            | 81.8 (78.8–87.2)              |
| FIB-4 score                     | 2.7 (2.2–3.0)                 |
| HBeAg-positive, n (%)           | 34 (19.4%)                    |
| Detectable HBV DNA level, IU/mL | 14.0 (12.4–16.5)              |
| Undetectable HBV DNA, n (%)     | 142/175 (81%)                 |

Data are expressed as n (%) for categorical data and as mean ± standard deviation or median (interquartile range) for continuous data.

ETV-Brand, entecavir-brand drugs; BMI, body mass index; WBC, white blood cell; HB, hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, Fibrosis-4; HBeAg, Hepatitis B e antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid.
of 6 months treatment of ETV-Generic, it showed 142 (81%) to 154 (88%) without significant, \(p=0.05\), see Fig. 2.

**Secondary end point of efficacy: comparing initial ALT and 6 months data of the treatment of ETV-Generic**

For all included patients, ALT kept normal from Brand to Generic with ALT: 27.2 IU/mL (CI: 24.8–29.6) to 26.2 IU/mL (CI 24.0–28.4) respectively showed no significant, \(p=0.55\), see Fig. 3.

**Adverse events**

All adverse events were recorded showed no significant symptoms during the treatment either ETV-Brand or ETV-Generic. The major safety profile was a renal outcome issue of eGFR changes. Comparing with ETV-Brand and ETV-Generic, eGFR changes showed 80.8 mL/min/1.73 m\(^2\) (IQR: 66.6–95.3) to 80.3 mL/min/1.73 m\(^2\) (IQR: 65.6–93.5) without statistical significant, \(p=0.59\), see Fig. 4.

**Discussions**

In this real-world study, we found the switching from ETV-Brand to ETV-Generic is safe and the anti-viral efficacy was maintained.

CHB imposes a significant global health care burden; approximately 5% of individuals throughout the world are estimated to be infected with HBV [18], and the annual mortality associated with persistent HBV infection is more than 1 million per year [19]. Mother-to-child transmission is the driving force of new HBV infections in high prevalence countries especially in Asia [20, 21].

In addition to making national wide-ranging treatments possible through standard therapies, affordable entecavir will benefit more HBV patients. With the popularization of hepatitis B vaccination, significant effects have been achieved in suppressing the spread of hepatitis B virus [22]. Therefore, by treating more than 350 million chronically infected people, the continued spread of the virus can be prevented [23]. International guidelines recommend ETV and tenofovir (TDF) as the first-line therapy for initial CHB-patients because of its strong antiviral activity and higher genetic barrier.
[24, 25]. Compared with TDF, basic patents expire in 2017 [26], entecavir is already generic in several countries, including the United States of America (USA) and Europe. In 2017, due to the introduction of tenofovir and entecavir generics in Germany, the treatment costs decreased by 31% with average therapy costs at 498 Euro per patient per month in 2016 and decreased to 214 Euro in 2019 and causing the increase in the number of CHB patients on treatment leading to the prevention of progression to more severe disease [27]. The basic patent for ETV-Brand in the USA was invalidated in 2014 [28]. In China and Brazil, the basic patents expired in 2011 [29]. In terms of price, generic ETV can be more feasible in developing or undeveloped country [30].

Generic medication is common in use for hypertension such as Amlodipine Besylate (Norvasc®) after the patent invalidated in 2007. Previous studies had shown the same efficacy comparing with generic and brand medication [31]. For now, there is little data regarding the real-world result of efficacy of using generic antiviral therapy in chronic hepatitis B.

We acknowledge that there are several limitations, including small sample size and no placebo control study, retrospective not randomized study, and a single center study. Further studies with a prospective, quasi-experimental approach still highly needed to explain the further effectiveness and safety of ETV-Generic.

The advantages of this study are (1) A first real-world data comparing ETV-Brand to ETV-Generic in Asian countries (2) Pointing out of generic drugs for virus eradication especially of CHB in the global health is important.

Conclusion
In patients with previously untreated HBV infection, the efficacy and safety profiles of switching from ETV-Brand to ETV-Generic showed no difference. Concluding the ETV-Generic comes to exciting virologic responses and adverse events. Therefore, affordable generic drugs may be widely used in undeveloped and developing countries to treat hepatitis B. But it still needs to be confirmed by further studies in the future.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12876-022-02317-7.

Additional file 1: Raw data.

Acknowledgements
All authors thank the Department of Hepatology and Gastroenterology at Changhua Christian Hospital for their generous help.

Author contributions
PKH and CLW have full access to all data in the study and take the responsibility of data integrity and accuracy of analysis. PKH, YPS, CLW, draft the manuscript and perform the study; CLW, PNH, analysis the data and approve the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by Grants 109-CCH-IRP-028 and MOST 110-2628-B-371-001 from the Changhua Christian Hospital Research Foundation and the Ministry of Science and Technology of Taiwan, respectively. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
All data generated during this study are included in the published article and Additional file 1 of Raw data.

Declarations

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of Changhua Christian Hospital (CCH IRB, No. 2020-02). All patients have signed an informed consent form, which has been certified by the Institutional Review Board, and we signed a confidentiality agreement to protect the rights and interests of patients.

Consent for publication
Not applicable.

Competing interests
The authors report no conflicts of interests in this work.

Author details
1 Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan. 2Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. 3School of Medicine, Chung Shan Medical University, Taichung, Taiwan. 4Division of Nephrology, Changhua Christian Hospital, Changhua, Taiwan. 5School of Medicine, National Chung Hsing University, Taichung, Taiwan.

Received: 24 December 2021 Accepted: 4 May 2022

References
1. Breiner KM, Schaller H, Knolle PA. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms. Hepatology (Baltimore, MD). 2001;34(4):803–8.
2. Lavaney D, Kane M. Global epidemiology of hepatitis B virus infection. In: Liaw Y-F, Zoulim F, editors. Hepatitis B virus in human diseases. Cham: Springer; 2016. p. 187–203.
3. Kew M. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58(4):273–7.
4. Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepatitis. 2021;28(3):493–507.
5. Hutan Y, Nasrullah M, Easterbrook P, Dongmo Nguimfack B, Burrone E, Averhoff F, et al. Access to treatment for hepatitis B virus infection worldwide, 2016. Am J Transplant. 2018;18:2595–8.
6. Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;6:106–19.
7. Lo K-J, Tsai Y, Lee S-D, Yeh C, Wang J, Chiang B, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology. 1985;32(2):65–8.
8. Hsu H. Hepatitis B control and its implementation. Epidemiology of Hepatitis B and Implementation of Immunophrophylaxis in Taiwan [in Han-Chinese] Taipei, Taiwan: Department of Health; 1989. p. 95–105.

9. Chen D-S, Hsu NH-M, Sung J-L, Hsu T-C, Hsu S-T, Kuo Y-T, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen—carrier mothers. JAMA. 1987;257(19):2597–603.

10. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18(4):301–7.

11. Chen H-L, Chang M-H, Ni Y-H, Hsu H-Y, Hsu P-I, Lee C-Y, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996;276(11):906–8.

12. Kumar R, Pérez-del-Pulgar S, Testoni B, Lebossé F, Zoulim F. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Liver Int. 2016;36:72–7.

13. Martinez MIG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections. J Hepatol. 2021;75:706–17.

14. Do Young Kim JHK, Tak WY, Yeon JE, Lee JH, Yoon JH, Lee YJ, et al. Baraclude® vs Baraclude® for 48 weeks in patients with treatment-naive chronic hepatitis B: a comparison of efficacy and safety. Drug Design Dev Ther. 2017;11:3145.

15. Jones S, Murakami E, Delaney W, Furman P, Hu J. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother. 2013;57(9):4181–9.

16. Toy M, Hutton DW, So SK. Cost-effectiveness and cost thresholds of generic and brand drugs in a national chronic hepatitis B treatment program in China. PLoS ONE. 2015;10(11): e0139876.

17. Ahn YE, Suh SJ, Kim TH, Jung YK, Yim HJ. Maintaining antiviral efficacy after switching to generic entecavir 1 mg for antiviral-resistant chronic hepatitis B. Korean J Gastroenterol. 2021;77(1):22–9.

18. Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677–87.

19. Razavi H. Global epidemiology of viral hepatitis. Gastroenterol Clin N Am. 2020;49(2):179–89.

20. Lansang M. Epidemiology and control of hepatitis B infection: a perspective from the Philippines. Asia Gut. 1996;38(Suppl 2):S43–7.

21. Franco-Moreno J, Moore P, Combe E, Testoni B, Zoulim F. Relevance of the study of hepatitis B virus covalently closed circular DNA. J Viral Hepatol. 2016;36:72–7.

22. Martinez MIG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections. J Hepatol. 2021;75:706–17.

23. Ahn YE, Suh SJ, Kim TH, Jung YK, Yim HJ. Maintaining antiviral efficacy after switching to generic entecavir 1 mg for antiviral-resistant chronic hepatitis B. Korean J Gastroenterol. 2021;77(1):22–9.

24. Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677–87.

25. Razavi H. Global epidemiology of viral hepatitis. Gastroenterol Clin N Am. 2020;49(2):179–89.

26. Toy M, Hutton DW, So SK. Cost-effectiveness and cost thresholds of generic and brand drugs in a national chronic hepatitis B treatment program in China. PLoS ONE. 2015;10(11): e0139876.

27. Ahn YE, Suh SJ, Kim TH, Jung YK, Yim HJ. Maintaining antiviral efficacy after switching to generic entecavir 1 mg for antiviral-resistant chronic hepatitis B. Korean J Gastroenterol. 2021;77(1):22–9.

28. Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677–87.

29. Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Dev Ther. 2014;8:13.

30. Xu K, Liu L-M, Farazi PA, Wang H, Rochling FA, Watanabe-Galloway S, et al. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. Glob Health Action. 2018;11(1):1435987.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.